Vanderbilt Network Lead Academic Participating Site for the NCTN

范德比尔特网络 (Vanderbilt Network) 主导 NCTN 学术参与网站

• 批准号: 9238456
• 负责人: JORDAN D BERLIN
• 金额: $ 59.22万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9238456
• 关键词: Advisory Committees; Affect; American College of Surgeons Oncology Group; Antineoplastic Agents; Area; Authorship; Award; Basic Science; Berlin; Breast; Budgets; Cancer Center; Cancer Patient; Clinical Cancer Center; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Collection; Complement; Country; Data; Detection; Development; Diagnosis; Discipline; Disease; Doctor of Medicine; Drug resistance; Early Detection Research Network; Eastern Cooperative Oncology Group; Ensure; Epigenetic Process; Faculty; Goals; Grant; Gynecologic Oncology Group; Image; Institutes; Institution; Institutional Review Boards; Jordan; Lead; Leadership; Lung; Malignant Neoplasms; Malignant neoplasm of pancreas; Manuscripts; Medical; Medicine; Mentors; Mission; Mutation; National Clinical Trials Network; Patient Care; Patients; Phenotype; Physicians; Process; Proteome; Proteomics; Protocols documentation; Radiology Specialty; Research; Research Infrastructure; Research Personnel; Resource Sharing; Role; Science; Scientist; Site; System; Technology; Time; Translational Research; Universities; Work; cancer care; cancer genomics; design; drug development; drug discovery; improved outcome; inter-institutional; interest; medical specialties; meetings; member; multidisciplinary; next generation; programs; public health relevance; radiological imaging; targeted treatment; tumor; web site

DESCRIPTION (provided by applicant): Vanderbilt-Ingram Cancer Center (VlCC) is a matrix cancer center within Vanderbilt University. VlCC trials been part of the cooperative group system for 24 years, as a member of the Eastern Cooperative Oncology Group, the Gynecologic Oncology Group (GOG) and the American College of Surgeons Oncology Group (ACOSOG). In this role, we have integrated our physicians into leadership roles and our science into the clinical trials and accrued patients into trials. The VlCC selected Jordan Berlin, MD, as PI to lead the efforts of the institution to integrate its scientific, academic and patient resourcs into the new NCTN. He has been involved extensively In the cooperative groups in both clinical trials and leadership. He has also been a successful mentor. To maintain a broad representation across medical disciplines and disease interests, two leadership boards were created. The internal advisory board (lAB) assures the optimum use of the grant such as budget review, assuring multidisciplinary involvement and participation throughout the NCTN while the NCTN Executive Committee (NEC) implements operational functions such as trial opening, accrual, and mentoring. Both the lAB and NEC will work to integrate VlCC science into the NCTN. The VlCC Clinical Trials Shared Resource and its NCTN team will ensure that regulatory and biospecimen/radiology data submissions are timely and highly accurate. VlCC has a long track record of leadership, both scientific and administrative, within the cooperative groups, integrating basic science into clinical trials and helping junior faculty in trial development. VlC brings great strengths to the NCTN including two SPORE grants, two EDRN grants, a world class Institute of Imaging Science, advanced capabilities in proteomics and a superb Center for Quantitative Sciences. Our Personalized Cancer Medicine Initiative is dedicated to answering Provocative Question B5 (How does the order in which mutations or epigenetic changes occur alter cancer phenotypes or affect the efficacy of targeted therapies?), and bringing the data from drug resistance-associated mutations into clinical trials. This is complemented by MyCancerGenome, a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for patients whose tumors harbor actionable genetic alterations The team of VlCC scientists, academic leaders and junior Investigators will significantly contribute to the NCTN goals and, as a result, improve the outcomes for cancer patients.

描述（由申请人提供）：Vanderbilt-Ingram癌症中心（VlCC）是范德比尔特大学内的基质癌症中心。作为东部肿瘤协作组、妇科肿瘤协作组（GOG）和美国外科医师学会肿瘤协作组（ACOSOG）的成员，VLCC试验已成为协作组系统的一部分长达24年。在这个角色中，我们将我们的医生融入领导角色，将我们的科学融入临床试验，并将患者纳入试验。VLCC选择医学博士Jordan柏林作为PI，领导该机构将其科学、学术和患者资源整合到新的NCTN中。他在临床试验和领导方面广泛参与了合作小组。他也是一位成功的导师。为了在医学学科和疾病领域保持广泛的代表性，成立了两个领导委员会。内部咨询委员会（IAB）确保最佳使用赠款，如预算审查，确保多学科参与和参与整个NCTN，而NCTN执行委员会（NEC）执行业务职能，如审判开放，应计和指导。IAB和NEC都将致力于将VLCC科学纳入NCTN。VLCC临床试验共享资源及其NCTN团队将确保及时且高度准确地提交监管和生物标本/放射学数据。VLCC在合作小组内有着长期的科学和行政领导记录，将基础科学融入临床试验，并帮助初级教师进行试验开发。VlC为NCTN带来了巨大的优势，包括两项SPORE赠款、两项EDRN赠款、世界一流的成像科学研究所、蛋白质组学的先进能力和一流的定量科学中心。我们的个性化癌症医学计划致力于回答挑衅性问题B5（突变或表观遗传变化发生的顺序如何改变癌症表型或影响靶向治疗的疗效？），并将耐药性相关突变的数据带入临床试验。MyCancerGenome是一个网站，它不仅向医生提供最新的癌症基因组学信息，而且还为肿瘤携带可操作的遗传改变的患者提供试验。VLCC科学家，学术领袖和初级研究人员团队将为NCTN目标做出重大贡献，从而改善癌症患者的预后。